ATLASImmunovant (IMVT) Q2 fiscal 2027 earnings results
Immunovant (IMVT) reported EPS of -$0.41 against an analyst estimate of -$0.73: a beat of $0.32 (43.8%). The quarter ended Sep 30, 2026; the company reported on Monday, November 9, 2026, before the open.
Status: Confirmed · 14:37 ET, Nov 9 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Immunovant reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountIMVT Q2 fiscal 2027 results at a glance
| EPS reported | -$0.41 |
|---|---|
| EPS estimate | -$0.73 |
| Surprise | Beat · +$0.32 (+43.8%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 9, 2026, before the open |
| Status | Confirmed · 14:37 ET, Nov 9 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. Immunovant’s fiscal year ends in March, so the quarter ended Sep 30, 2026 is its Q2 fiscal 2027.
Immunovant EPS surprise history: last 5 quarters
Immunovant beat the EPS estimate in 3 of its last 5 reports, with an average surprise of +11.7%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 9, 2026 | -$0.73 | -$0.41 | +43.8% | Beat | – |
| Aug 6, 2026 | -$0.61 | -$0.68 | -11.5% | Miss | +1.7% |
| May 20, 2026 | -$0.63 | -$0.67 | -6.3% | Miss | +29.8% |
| Feb 6, 2026 | -$0.69 | -$0.54 | +21.7% | Beat | +14.3% |
| Nov 10, 2025 | -$0.73 | -$0.65 | +11.0% | Beat | -2.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
IMVT stock reaction to the report
IMVT moved +15.17% in the first session that reflects the report (close of Nov 6, 2026 $30.53 to close of Nov 9, 2026 $35.16).
Next IMVT earnings report
Immunovant has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the IMVT earnings calendar.
ATLAS fair value and signal for IMVT
| Last price | $34.54 (+13.1%) |
|---|---|
| Chance of a higher close in 1 month | 48% (normal range $31.45–$37.54) |
These are model outputs from the same valuation and calibrated model as the Immunovant stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Immunovant Q2 fiscal 2027 earnings: frequently asked questions
Did Immunovant beat earnings estimates for Q2 fiscal 2027?
Immunovant reported EPS of -$0.41 against an analyst estimate of -$0.73: a beat of $0.32 (43.8%).
When did Immunovant report Q2 fiscal 2027 results?
Immunovant reported on Monday, November 9, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does IMVT beat EPS estimates?
In its last 5 reports with a recorded result, Immunovant beat the EPS estimate 3 times; the average surprise was +11.7%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer